William A. Wargin

Also affiliated with Tris Pharma (United States)

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “A phase 2, multicenter, double-blind, randomized, placebo-controlled study of the safety and efficacy of forvisirvat (SP-624) in the treatment of adults with major depressive disorder”.

A phase 2, multicenter, double-blind, randomized, placebo-controlled study of the safety and efficacy of forvisirvat (SP-624) in the treatment of adults with major depressive disorder

Current Medical Research and Opinion(2025)10.1080/03007995.2025.2574465

N/A

0.104DataRank · unranked

1 citations

Anita H. Clayton, Susan G. Kornstein, George I. Papakostas, Yuki Prescott, Kelly Abernathy +6 more

Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion

UNC Libraries(2020)10.17615/dcmz-4678

N/A

0DataRank · unranked

4 citations

William A. Wargin, Shenghui He, Jessica A. Sorrentino, Ewoud‐Jan van Hoogdalem, Jay C. Strum +8 more

A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease

UNC Libraries(2020)10.17615/r612-td45

N/A

0DataRank · unranked

0 citations

William A. Wargin, Marvin Reid, Abdullah Kutlar, Susan P. Perrine, Richard Labotka +7 more